Troxerutin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Troxerutin
DrugBank Accession Number
DB13124
Background

Troxerutin has been used in trials studying the treatment of Chronic Venous Insufficiency.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 742.6752
Monoisotopic: 742.232029162
Chemical Formula
C33H42O19
Synonyms
  • Troxerutin
  • Troxerutina

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Symptomatic treatment ofCapillary fragility•••••••••••••••••• •••
Symptomatic treatment ofChronic venous insufficiency (cvi)•••••••••••••••••• •••
Treatment ofChronic venous insufficiency (cvi)•••••••••••••••••••• ••••••• ••• ••••••••
Used in combination to treatHemorrhoidsCombination Product in combination with: Ginkgo biloba (DB01381), Heptaminol (DB13574)••• ••••••••••
Symptomatic treatment ofLymphoedema•••••••••••••••••• •••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Troxerutin.
AceclofenacThe risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Troxerutin.
AcemetacinThe risk or severity of bleeding and hemorrhage can be increased when Troxerutin is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Acenocoumarol is combined with Troxerutin.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Troxerutin.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Elas gelTroxerutin (3000 mg/100g) + Ginkgo biloba (140 mg/100g)LotionTopicalCho-A Pharm.Co.,Ltd.2017-02-28Not applicableUS flag
Elas gelTroxerutin (1500 mg/50g) + Ginkgo biloba (70 mg/50g)LotionTopicalCho-A Pharm.Co.,Ltd.2019-03-23Not applicableUS flag
GINKOR FORT CAPSULETroxerutin (300 mg) + Ginkgo biloba (14 mg) + Heptaminol hydrochloride (300 mg)CapsuleOralEP PLUS GROUP SDN. BHD.2020-09-08Not applicableMalaysia flag
LACORYL® T SACHETTroxerutin (0.02 g) + Troxerutin (0.4 g)Powder, for solutionOralLABORATORIOS SYNTHESIS S.A.S.2007-01-29Not applicableColombia flag
LACORYL® T SACHETTroxerutin (0.02 g) + Troxerutin (0.4 g)Powder, for solutionOralLABORATORIOS SYNTHESIS S.A.S.2007-01-29Not applicableColombia flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Elas gelTroxerutin (3000 mg/100g) + Ginkgo biloba (140 mg/100g)LotionTopicalCho-A Pharm.Co.,Ltd.2017-02-28Not applicableUS flag
Elas gelTroxerutin (1500 mg/50g) + Ginkgo biloba (70 mg/50g)LotionTopicalCho-A Pharm.Co.,Ltd.2019-03-23Not applicableUS flag

Categories

ATC Codes
C05CA04 — TroxerutinC05CA54 — Troxerutin, combinations
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as flavonoid-3-o-glycosides. These are phenolic compounds containing a flavonoid moiety which is O-glycosidically linked to carbohydrate moiety at the C3-position.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Flavonoids
Sub Class
Flavonoid glycosides
Direct Parent
Flavonoid-3-O-glycosides
Alternative Parents
5-hydroxyflavonoids / Flavones / Chromones / Disaccharides / O-glycosyl compounds / Phenoxy compounds / Phenol ethers / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Alkyl aryl ethers
show 11 more
Substituents
1-benzopyran / 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / 5-hydroxyflavonoid / Acetal / Alcohol / Alkyl aryl ether / Aromatic heteropolycyclic compound / Benzenoid / Benzopyran
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
7Y4N11PXO8
CAS number
7085-55-4
InChI Key
IYVFNTXFRYQLRP-VVSTWUKXSA-N
InChI
InChI=1S/C33H42O19/c1-14-23(38)26(41)28(43)32(49-14)48-13-21-24(39)27(42)29(44)33(51-21)52-31-25(40)22-17(37)11-16(45-7-4-34)12-20(22)50-30(31)15-2-3-18(46-8-5-35)19(10-15)47-9-6-36/h2-3,10-12,14,21,23-24,26-29,32-39,41-44H,4-9,13H2,1H3/t14-,21+,23-,24+,26+,27-,28+,29+,32+,33-/m0/s1
IUPAC Name
2-[3,4-bis(2-hydroxyethoxy)phenyl]-5-hydroxy-7-(2-hydroxyethoxy)-3-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-({[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-4H-chromen-4-one
SMILES
C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(OCCO)=CC(O)=C4C3=O)C3=CC(OCCO)=C(OCCO)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O

References

General References
Not Available
Human Metabolome Database
HMDB0006083
PubChem Compound
5486699
PubChem Substance
347829247
ChemSpider
4589027
RxNav
38893
ChEMBL
CHEMBL3182320
ZINC
ZINC000085552699
Wikipedia
Troxerutin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentChronic Venous Insufficiency (CVI)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
LotionTopical
Injection, solutionIntramuscular
Tablet, coatedOral
CapsuleOral
GelTopical
Powder, for solutionOral
TabletOral300.000 mg
GelTopical2 %
Capsule
Cream
Solution / dropsOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.43 mg/mLALOGPS
logP-0.55ALOGPS
logP-2.5Chemaxon
logS-2.7ALOGPS
pKa (Strongest Acidic)7.14Chemaxon
pKa (Strongest Basic)-2.8Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count19Chemaxon
Hydrogen Donor Count10Chemaxon
Polar Surface Area293.21 Å2Chemaxon
Rotatable Bond Count15Chemaxon
Refractivity172.47 m3·mol-1Chemaxon
Polarizability73.12 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fbd-1003196700-5fd3e46de7204572a34a
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0000009000-040539ae19bcf7f13cf3
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0000009100-358d729c67d68605715d
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0f97-0503197700-c5f30853686123f73427
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0009306200-bd23e4f5ff2d3d93dcda
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-000l-1101097500-b1788f3f7275004eb740
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-259.5999425
predicted
DarkChem Lite v0.1.0
[M-H]-260.3975425
predicted
DarkChem Lite v0.1.0
[M-H]-249.18747
predicted
DeepCCS 1.0 (2019)
[M+H]+258.3622425
predicted
DarkChem Lite v0.1.0
[M+H]+262.8876425
predicted
DarkChem Lite v0.1.0
[M+H]+251.47023
predicted
DeepCCS 1.0 (2019)
[M+Na]+259.9914425
predicted
DarkChem Lite v0.1.0
[M+Na]+265.1234425
predicted
DarkChem Lite v0.1.0
[M+Na]+257.41302
predicted
DeepCCS 1.0 (2019)

Drug created at October 21, 2016 03:27 / Updated at February 21, 2021 18:54